Role of Melatonin in Treatment of Necrotizing Enterocolitis in Preterm Neonates

AZZA M.A. GAD ALLAH, M.Sc.*; MOSTAFA M.A. EL-HUSSENY, M.D.*; NAHED M. ELWAN, M.D.** and MOHAMED Sh. EL-FARARGY, M.D.*

The Departments of Pediatrics* and Clinical Pathology**, Faculty of Medicine, Tanta University

Abstract

Background: Necrotizing enterocolitis (NEC) is one of the most dangerous gastrointestinal diseases that affects the neonates especially preterm neonates. It can lead to severe morbidity and even mortality, so early detection of NEC would give us good chance for early prevention and treatment with better prognosis. Free radicals play a significant role in the pathogenesis of neonatal sepsis and NEC. It has been suggested that melatonin as an antioxidant can be used to counteract the toxicity of oxygen radicals that are released during neonatal illness.

Aim of Study: Is to Determine the role of melatonin as an adjuvant therapy in treating necrotizing enterocolitis (NEC) in preterm neonates.

Patients and Methods: A prospective clinical trial study was conducted on 20 preterm neonates which suffer from NEC diagnosed on the basis of both clinical and laboratory criteria. group (G I) (n=10) received melatonin and antibiotics, while the control group (G II) (n=10) was treated with antibiotics only. Melatonin was administered as 20 mg for 3 consecutive days and antibiotics were administered according to a standard protocol and followed-up of symptoms and signs of NEC after 5, 10 and 15 days of starting treatment.

Results: As regard outcome of NEC, In group I there were 9 (90%) cases improved and 1 (10%) case not improved but in group II there were 5 (50%) cases improved and 5 (50%) cases not improved, so more cases in group I who received melatonin showed improvement of NEC than group II. As regard mortality, one baby (10%) died and 9 (90%) survived in group I compared to 3 babies (30%) died and 7 babies (70%) survived in group II. As regard length of NICU stay the patients who received melatonin (group I) stay for a shorter period in NICU compared to group II who received traditional therapy only.

Conclusion: Melatonin administration as an adjuvant therapy in NEC treatment in preterm neonates is associated with improvement of clinical and laboratory outcome.

Key Words: Preterm neonates – Necrotizing enterocolitis – Melatonin.

Introduction

NECROTIZING enterocolitis (NEC) is one of the commonest gastrointestinal surgical emergency in premature infants less than 37 weeks and less than 1.500gm [1]. Preterm neonates are more susceptible to Oxidative Stress (OS) damage than full term infants due to prematurity of organs, rapidly increasing energy demand, production of excessive Reactive oxidative stress (ROS) and the deficiency of antioxidant systems that come to maturity later [2].

Necrotizing enterocolitis is an inflammatory disease of gastrointestinal tract, present with multifactorial etiology [3]. Oxidative stress and exaggerated inflammatory response in the premature Gut, abnormal intestinal bacterial colonization play a role in pathogenesis of NEC, prematurity, enteral feeding, hypoxia and intestinal ischemia are also involved in the pathogenesis of the disease [4].

The combination of immature antioxidant defense system and elevated levels of ROS place the neonate in high risk of intestinal damage, but this injury can be improved by using radical scavenger

Melatonin is a highly active free radical scavenger [5]. It has many physiological functions in circadian rhythm, sleep neuroendocrine, and cerebrovascular systems [6]. Melatonin also has important role as an antioxidant, anti-inflammatory and anti-apoptotic agent [7,8].

Melatonin has been to be effective in reducing molecular damage, tissue loss and improving physiological outcome as chronic lung disease, perinatal brain injury, NEC and sepsis [9]. Effects of melatonin in preventing gastrointestinal disturbances
were studied in rat [10]. Studies demonstrates that TNF-cyt and IL28 were decreased in animal model after NEC and treated with melatonin [10]. So it is possible that antioxidant melatonin might be useful in management of neonate with NEC.

Aim of the work:

Is to evaluate the role of melatonin in treatment of necrotizing enterocolitis in preterm neonates.

Patients and Methods

This study was carried out on 20 preterm neonates suffering from NEC and conducted at NICU in Tanta University Hospital during the period from January 2017 to December 2017. Patients were subdivided in two groups:

- Group (I): Included 10 preterm neonates who received antibiotics as standard protocol and oral melatonin 20mg/day once.
- Group (II): Included 10 preterm neonates who received antibiotics only as standard protocol.

All patients were subjected to:

A- Full history taking and thorough clinical examination

B- Investigations: Complete blood count, renal functions, liver functions, C reactive protein (CRP), capillary blood gases, serum electrolytes (Na, K, Ca, Mg).

C- Radiological investigations: Pelvi-abdominal US, X-ray abdomen and pelvis.

D- Melatonin was administrated as 20mg for 3 consecutive days, antibiotics were given according to a standard protocol and followed-up of symptoms and signs of NEC after 5, 10 and 15 days of starting treatment in addition to followed-up by laboratory investigations.

Results

This study was carried out on 20 preterm neonates with NEC.

Table (1) showed there was non significant difference regarding gender, gestational age and weight between both groups.

Fig. (1) showed all cases in patients and controls (100%) presented by increase abdominal girth and there was no significant difference before starting treatment. Significant difference of abdominal circumference between both groups on D5, D10 and D15. Significant difference in both groups at D5, D10 and D15 on comparison between before and after receiving treatment.

Fig. (2) showed all (100%) cases in group I and group II presented by feeding residual. After starting treatment we noticed that, Significant improvement as regard feeding residual in both groups on comparison between before and after receiving treatment on D15 only. Significant improvement as regard feeding residual in D5, D10 and D15 in group I who received melatonin on comparison to D10 and D15 in group II who received traditional treatment.

Fig. (3) showed six (60%) cases of group I and group II presented by thrombocytopenia before starting treatment. After starting treatment there was significant improvement of thrombocytopenia to reach to normal platelets count in group I who received melatonin than group II who received traditional treatment. Significant difference in both groups at D15 in comparison between before with D5, D10 and D15 in each group.

Fig. (4) showed on comparison before and after treatment in each group we found that Significant improvement of serum bicarbonate level as returned to normal values in patients who received melatonin (group I) treatment on D10 and D15 while significant improvement of group II at D10 only.

Fig. (5) showed six (60%) cases of group I and eight (80%) cases of group II presented with hyponatremia before starting treatment.

Fig. (6) showed significant difference as the patients who received melatonin (group I) stay for a shorter period in NICU compared to group II who received traditional therapy only.

Fig. (7) showed in group I there were 90% of cases improved and 10% of cases not improved but in group II there were 50% of cases improved and 50% of cases not improved. Significantly more cases in group I who received melatonin showed improvement of NEC than group II who received only traditional treatment.
Table (1): Demographic data (gender, gestational age and weight) of the studied groups.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Chi-Square or t-test</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$X^2$ or $t$</td>
</tr>
<tr>
<td>Group I (n=10)</td>
<td>Group II (n=10)</td>
</tr>
</tbody>
</table>

**Gender:**
- Male: 5 (50.00), 2 (20.00)
  - $X^2 = 1.978$, $p = 0.160$
- Female: 5 (50.00), 8 (80.00)

**Gestational age (Week):**
- Range: 30–33, 27–34
- Mean ±SD: 31.800 ± 1.229, 31.200 ± 2.530
- $t = 0.675$, $p = 0.509$

**Weight (kg):**
- Range: 1.5–2.2, 1.4–2.1
- Mean ±SD: 1.910 ± 0.288, 1.710 ± 0.251
- $t = 1.656$, $p = 0.115$

Fig. (1): Comparison between studied groups as regard abdominal girth.

Fig. (2): Comparison between studied groups as regard feeding residual.

Fig. (3): Comparison between studied groups as regard platelets count.

Fig. (4): Comparison between studied groups as regard serum bicarbonate level.

Fig. (5): Comparison between studied groups regard serum sodium.
Role of Melatonin in Treatment of Necrotizing Enterocolitis in Preterm Neonates

Discussion

In our study there was statistically no significant difference among all studied groups as regard demographic data (gestational age, weight and gender) and this in agreement with El-Farargy et al., who used melatonin as an adjuvant therapy in neonatal sepsis [11].

In our study there was statistically significant difference between both groups as regard vomiting and feeding residual as there was more improvement in group I treated with melatonin more than group II and this is in agreement with Pereira who reported that dietary supplementation of melatonin resulted in remarkable remission in gastroesophageal reflux disease [12]. Kesik et al., showed the healing effect of melatonin in ischemia-reperfusion model in rats so decreased symptoms and signs of GIT disturbances [13].

As regard abdominal girth we found that there was Significant difference between both groups on comparison between before and after receiving treatment as there was significant improvement and decreased abdominal girth to normal range in group I more than group II This agreed with Esteban-Zubero et al., [14] who studied role of melatonin as co-adjuvant treatment in colonic diseases.

There was significant difference as regard platelets count between both groups as there was significant improvement in thrombocytopenia in group I who received melatonin more than group II and in agreement with Lissoni et al., [15]. Who showed protective effects on platelet recovery by administration of melatonin have already been shown in an irradiated mouse model and in patients with thrombocytopenia. Also in agreement with this study El-Farargy and Soliman [16]. Who used melatonin as adjuvant therapy in necrotizing enterocolitis in neonates.

The present study found significant difference in metabolic acidosis, hyponatremia between preterm neonates at the onset of the research and after 5, 10 and 15 days of onset as there was significant improvement in group I who received melatonin more than group II in agreement with this study El-Farargy and Soliman [16]. Who used melatonin as adjuvant therapy in necrotizing enterocolitis in neonates.

As regard outcome of NEC it was observed that in Group I there were 90% cases improved and 10% case not improved but in Group II there were 50% of cases improved and 50% of cases not improved and this showed significantly improvement of cases in group I who received melatonin than group II who received antibiotics only. As the NEC is apart of sepsis so this is in agreement with Gitto et al., [8] who had shown that melatonin has anti-inflammatory effect in neonates suffering from neonatal sepsis if it is added as an adjuvant therapy and there was significant improvement in group suffering from neonatal sepsis treated with melatonin and antibiotics.

There was significant difference between melatonin and traditional therapy groups as regard length of stay in hospital as group I who received melatonin stay for a shorter period in NICU compared to group II who received traditional therapy without melatonin.

Conclusion:
Administration of melatonin as an adjuvant therapy in the treatment of NEC in preterm neonates is associated with improvement of clinical and laboratory outcome.
Acknowledgments:
This research was carried out without funding.

Conflicts of interest:
No conflicts of interest declared.

Authors' contributions:
All authors had equal role in design, work, statistical analysis and manuscript writing. All authors have approved the final article work.

References
دور الميلاتونين في علاج ناخر الأمعاء في الأطفال حديثي الولادة
غير مكتمل النمو

يعتبر ناصر الأمعاء ما يطرأ على جراحة الجهاز الهضمي في الأطفال الخضع أقل من 37 أسبوعا وأقل من 500 جم. ناصر الأمعاء هو مرضاً نتائج انسداد القناة البولية نتيجة للصفرات المتشكلة عند الاستجابة للالتهابات الناتجة عن الاستجابة البكتيرية غير طبيعية. يعتبر الميلاتونين هو أعلى مضادات الأكسدة الفعالة وبالتالي قد يكون مفيد في علاج ناصر الولادة المصابين بناخر الأمعاء.

الهدف من الدراسة: الهدف من هذه الدراسة هو تقديم دور الميلاتونين في علاج ناصر الأمعاء.

المرض وطرق البحث: تم عمل هذه الدراسة على 120 من الأطفال حديثي الولادة غير مكتمل النمو تم تقسيمهم إلى مجموعتين: المجموعة الأولى تشمل 100 حديثي الولادة يعانون من ناصر الأمعاء ويتلقيون علاجهم بالمضادات الحيوية والميلاتونين والمجموعة الثانية تشمل 10 حديثي الولادة يعانون من ناصر الأمعاء ويتلقيون علاجهم بالمضادات الحيوية فقط في حضانات مستشفى طنطا الجامعي العام.

النتائج: لوحظ أن المجموعة التي تم إضافة الميلاتونين إلى العلاج تحسن بشكل ملحوظ وأنخفضت أعراض المرض (القيء، إنتاج البطن).

الاستنتاج: يعتبر الميلاتونين له دور في علاج ناصر الأمعاء في الأطفال حديثي الولادة غير مكتمل النمو.

الوصفات: توضح إضافة الميلاتونين في علاج ناصر الأمعاء في الأطفال حديثي الولادة غير مكتمل النمو.